Importance of RAS/RAF/MEK/ERK pathway in human cancers

Thirty percent of all human cancers are driven by mutations of the RAS family of genes and are highly aggressive and recurrent. Despite decades of effort by academia and industry, there has been little progress in developing clinically effective treatments for cancers with these mutations, and they have been described as an elusive cancer target.

A lot of has been learned about the RAS pathway over the past decades. MEK inhibition has been clinically promising but insufficient on its own, which is why combination approach is key.


KRAS mutating cancers and RAF/MEK

NRAS mutating cancers